bluuebunny/crossref_metadata_2025_split huggingface dataset:
Rapid deployment bioprostesis for aortic valve stenosis: single center short and long-term outcomes
Authors: Ferreira R , Velho T , Sena A , Goncalves J , Junqueira N , Pereira R , Almeida A , Pinto F , Nobre A 
Published: October 2022

Abstract

Background
Despite recent advances, surgical aortic valve replacement (SAVR) remains the gold standard for most of the patients with aortic valve stenosis. The ageing population, with increased comorbidities and the rising of minimally invasive techniques, led to the development of new prosthetic devices of easier and faster implantation.

Purpose
This study aimed to analyse short and long-term outcomes of SAVR with rapid-deployment (RD) aortic bioprosthesis for isolated aortic valve stenosis

Method
Singe center, retrospective longitudinal cohort study of patients with isolated aortic valve stenosis who underwent elective aortic valve replacement using RD devices between 2014 and December 2021.
Continuous variables are presented with median (IQR) and were analyzed using Mann-Whitney test. Categorical variables are presented in percentage or frequency and were analyzed using chi-square test. Kaplan-Meyer survival curve was constructed base on collected data from national registry.

Results
A RD device was implanted in 358 patients with a median age of 75,8 years and Euroscore II of 2,3. Median cross clamp and extracorporeal circulation time were 27,4 and 36,7 min, respectively. No significant paravalvular leaks.
Intensive care unit (ICU) length of stay was 3 days with acute renal lesion (any stage-53,2%; Dialysis-2,5%), need for hemodynamic support (63,1%) and new onset atrial fibrillation (33,6%) being the most frequent post-operative complications. Stroke occurred in 0,6% of cases and mortality was 1,1%. Pacemaker implementation rate of 11%.
The mean follow-up time was 6,7 years with 90% 5-years survival rate. Mean gradients of 11,2±4,8 mmHg at 6 months

Conclusion
Surgical treatment of aortic valve stenosis using RD devices is safe, with a low mortality rate. ICU length of stay and hospital length of stay are reduced. Follow-up shows an excellent long-term survival and hemodynamic performance.

Funding Acknowledgement
Type of funding sources: None.
Edge-to-edge mitral valve repair improves concomitant high-grade tricuspid regurgitation
Authors: Groeger M , Zeiml K , Scheffler J K , Schoesser F , Schneider L M , Rottbauer W , Markovic S , Kessler M 
Published: October 2022

Abstract

Background
Mitral regurgitation (MR) and tricuspid regurgitation (TR) often occur simultaneously and symptoms of biventricular heart failure can overlap. There is currently no consensus on the management of combined MR and TR.

Purpose
To evaluate the impact of TR on echocardiographic and functional outcome after M-TEER.

Methods
740 patients underwent M-TEER for moderate-to-severe MR at our center from 2010 to 2021. Patients were analyzed according to severity of concomitant TR: low-grade TR (grade ≤ I (trace - mild)), moderate TR (grade II) and high-grade TR (grade III - V (severe - torrential)). After M-TEER, patients were followed up for 12 months and their echocardiographic and functional outcome was evaluated.

Results
Low-grade TR was present in 279 patients (37.7%), moderate TR in 170 patients (23.0%) and high-grade TR in 291 patients (39.3%) at the time of M-TEER procedure. Patients with moderate to high-grade TR had higher morbidity resulting in higher EuroSCORE II and STS-Score. At baseline more patients had MR grade ≥III in the high-grade TR group (92.8% vs. 87.1% in the low-grade TR group; p=0.023).
Procedural success of M-TEER was achieved similarly in all groups (98.2% vs. 97.6% vs. 95.9%, p=0.22). At discharge 87.6% of patients with low-grade TR and 80.9% of patients with high-grade TR had residual MR grade ≤I (p=0.036). Residual MR grade ≥III was present in 6.0% of low-grade TR patients and 10.5% of high-grade TR patients at discharge (p=0.062). 3 months after M-TEER residual MR ≥III increased to 9.4% vs. 13.4% (p=0.23) and after 12 months further increased to 12.3% vs. 15.3%, respectively (p=0.52).
TR grade decreased rapidly and consistently after M-TEER. 3 months after the procedure only 48.0% of high-grade TR patients still had TR grade ≥III (p&lt;0.001). After 12 months this proportion declined to 46.8% (p=0.99).
High-grade TR patients had significantly higher mortality (21.5% vs. 18.2% vs. 11.1%, p=0.003) up to 12 months after M-TEER. However, TR-grade ≥III did not independently predict mortality (HR 1.326, 95% CI 0.623–2.824, p=0.46).

Conclusion
M-TEER patients with concomitant moderate to high-grade TR had higher morbidity at baseline compared to low-grade TR patients. M-TEER was safe and effective in MR reduction independent of concomitant TR severity. However, high-grade TR patients had an increased risk for mortality after M-TEER, but high-grade TR did not independently predict adverse outcome. After M-TEER TR grade decreased rapidly and significantly in the high-grade TR group.

Funding Acknowledgement
Type of funding sources: None.
Topological data analysis identified prognostically-distinct phenotypes in MitraClip patients
Authors: Chao C , Seri A , Fortuin F D , Sweeney J P , Thaden J J , Eleid M , Alkhouli M , Rihal C R , Holmes D R , Pollak P M , Elsabbagh A , Lester S J , Oh J K , Banerjee I , Arsanjani R 
Published: October 2022

Abstract

Background
Topological data analysis (TDA) is the state-of-the-art unsupervised machine learning framework that can provide insight into the dataset and visualize condensed information via the topological network graph. This robust approach was never used to assess the heterogeneous MitraClip population.

Purpose
We aim to develop a TDA model that will identify prognostically-distinct phenogroups in MitraClip patients without a priori knowledge of the population and their outcomes.

Method
Patients who underwent MitraClip (June 2014-September 2020) at Mayo Clinic sites were identified from the institutional database for baseline and follow-up data. Thirteen variables were used for TDA. The topological network graph was created using the Python Scikit-TDA Kepler-Mapper package (v. 2.0.1), and clustering was performed at the graph level with Louvain's modularity method. Kaplan-Meier survival analysis was used to assess the all-cause mortality endpoint of each cluster identified in an unsupervised manner. The dataset with cluster labels was also used to train a Light Gradient Boosted Machine model, and SHapley Additive exPlanations (SHAP) analysis was applied to determine the feature importance.

Results
A total of 389 consecutive patients were included in the final analysis and two major clusters consisting of 384 patients were identified. The mean age was 80.3±8.7 years; 256 (65.8%) were male. The mean Society of Thoracic Surgeons Mitral Valve Replacement risk score was 9.6±6.9%. Fifty-five (14.5%) patients died during the mean follow duration (185 days). Kaplan-Meier analysis showed significant survival differences among the two clusters (HR: 2.38; 95% CI: 1.39–4.06, p=0.001; Figure 1). Clusters 1 (n=195) was associated with &gt; mild residual mitral regurgitation and worse survival performance and was characterized with worse tricuspid regurgitation severity, a higher proportion of patients with atrial fibrillation/flutter, anterior leaflet prolapse, and mitral annular/leaflet calcification, as summarized in Table 1.

Conclusion
TDA can identify distinct phenotype clusters with prognostic significance in MitraClip patients based on mitral valve morphology and clinical risk factors. This simple model can facilitate clinical risk stratification for MitraClip patients regarding procedural success and survival performance.

Funding Acknowledgement
Type of funding sources: None.
Aortic valve replacement for aortic stenosis in France – influence of centers' volumes on TAVR adoption rate and outcomes
Authors: Willner N A , Nguyen V , Eltchaninoff H , Burwash I G , Michel M , Durand E , Gilard M , Dindorf C , Iung B , Cribier A , Vahanian A , Chevreul K , Messika-Zeitoun D 
Published: October 2022

Abstract

Aims
Over the last decade, transcatheter aortic valve replacement (TAVR) became extensively used, now being the recommended as first line procedure for aortic valve replacement (AVR) in selected patients' populations. It is unknown whether TAVR adoption rate and variability in outcomes is influenced by centers' volume.

Methods
From a French administrative hospital-discharge database, we collected all AVR performed in France between 2007 and 2019. Centers were stratified to terciles based on their annual SAVR per year per center during 2007–2009 (“pre TAVR era”).

Results
There was 218,489 AVRs (153,747 SAVR and 74,732 TAVR) performed in 46 centers between 2007–2019. Number of total AVR and even more so number of number of TAVR significantly and linearly increased from 2007 to 2019 in all terciles but faster in the high volume tercile (+17, +17 and +31 AVR/center/year in the low, middle and high terciles respectively, P [ANCOVA]&lt;0.001; +11, + 19 and +33 TAVR/center/year in the low, medium and high tercile respectively, P [ANCOVA] &lt;0.00, Figure 1). The age of patients underwent TAVR remained grossly unchanged in all three terciles, however, the Charlson index declined from 2010 to 2019 (from 1.35±1.42 to 0.65±1.04, from 1.21±1.40 to 0.65±1.05 and from 1.53±1.58 to 0.81±1.21, in the low, middle and high terciles, P for trend &lt;0.001, 0.021, and &lt;0.001, respectively). Charlson score in the years 2017–2019, was higher in the high than middle and low terciles (0.87±1.22, 0.76±1.11 and 0.65±1.04, respectively, P&lt;0.0001). The in-hospital mortality rate for TAVR significantly declined from 2010 to 2019 for TAVR in all terciles (from 8.3% to 2.1%, from 7.5% to 2.5% and from 8.2% to 2.1% for low, middle and high TAVR terciles, respectively; p for trend = 0.002, 0.001 and &lt;0.001, respectively, Figure 2). Average mortality in 2017–2019 was similar in all terciles (2.3%, 2.5% and 2.2% for low, middle and high terciles, respectively, P=0.47). After adjusting for age, sex and Charlson score, mortality was higher in the low tercile compared with middle and high terciles (OR 1.15, P&lt;0.001, confidence interval [CI] 1.0–1.2, and OR 1.18, P&lt;0.001, CI 1.1–1.2, respectively).

Conclusions
From 2007 to 2019 total AVR linearly increased, mostly due to increase in TAVR, irrespective of centers' volume, but increase rate was higher in high volume centers. A constant decline in patients risk profile, with a striking decrease in mortality rate, was observed in all volume terciles. High-volume centers patients' have higher risk profile, with adjusted mortality slightly lower than medium and low volume centers.

Funding Acknowledgement
Type of funding sources: None.
Quantification of systolic anterior motion of the mitral valve to predict left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy
Authors: Verheyen N , Batzner A , Zach D , Zirlik A , Gerull B , Stoerk S , Maack C , Seggewiss H , Morbach C 
Published: October 2022

Abstract

Background
In patients with hypertrophic cardiomyopathy (HCM), left ventricular outflow tract obstruction (LVOTO) is associated with an increased risk of heart failure and death (1). It is typically caused by dynamic systolic anterior motion (SAM) of the mitral valve leaflet. SAM can be categorized by echocardiography but diagnostic accuracy is limited by high inter-observer variability.

Purpose
To investigate the accuracy of echocardiographic parameters quantifying systolic motion of the mitral valve leaflets to identify LVOTO in patients with HCM.

Methods
We present a cross-sectional analysis of the HyperCard Registry, a prospective single-center cohort study enrolling consecutive patients with suspected or confirmed HCM. For the present analysis, patients with confirmed HCM and a valid standardized transthoracic echocardiographic were included. LVOT gradients were measured at rest and during Valsalva maneuver using continuous wave Doppler. In patients with clinical suspicion of dynamic LVOTO, further provocation maneuvers were conducted. LVOTO was defined as a maximal peak LVOT gradient ≥30 mmHg. Parameters quantifying systolic motion of the mitral valve were measured in parasternal and apical views, both at early and late systole, by an investigator blinded to individual patient characteristics. SAM was visually assessed and categorized into grade 0 (no SAM), I (leaflet motion towards LVOT), II (late systolic septal contact), and III (early systolic septal contact).

Results
We analyzed 142 patients (59±13 years, 42% women). LVOTO was present in 68 (48%) patients of whom 30 (21% of all) exhibited LVOTO at rest, and 38 (27% of all) had LVOTO only during provocation maneuvers (ie. dynamic LVOTO). SAM was present in 86 patients (60%) and had a sensivitiy, specificity and PPV of LVOTO of 91%, 69% and 73%, respectively (table). The late-systolic distance between mitral leaflet tip and anterior septum (TISls) measured in apical 3-chamber view was best associated with the degree of SAM (F=123, P&lt;0.001), and with peak LVOT gradient (at rest: Pearson r=−0.817; during Valsalva maneuver: r=−0.816, both P&lt;0.001). In ROC analyses (figure), the AUC of TISls for identification of LVOTO and dynamic LVOTO were 0.914 (95% CI 0.868–0.959) and 0.857 (0.786–0.927), respectively. TISls ≤14 mm had a 97% sensitivity for LVOTO and of 94% for dynamic LVOTO. TISls ≤9 mm showed specificity and PPV of 95% and 92% for LVOTO, and 94% and 83% for dynamic LVOTO, respectively.

Conclusions
Quantification of SAM by TISls showed high diagnostic accuracy in identifying HCM patients with LVOTO. Prospective studies are needed to assess the incremental benefit of this novel parameter in the diagnostic work-up of HCM patients.

Funding Acknowledgement
Type of funding sources: None.
Transcatheter aortic-valve replacement with the self-expanding valve Portico in low-risk patients
Authors: Tamargo M , Gutierrez E , Vazquez M E , Sanz-Ruiz R , Diez-Delhoyo F , Soriano J , Elizaga J , Fernandez-Aviles F 
Published: October 2022

Abstract

Background
In the past years, transcatheter aortic-valve replacement (TAVR) has risen as a feasible and safe option for patients with aortic stenosis, been now an option of treatment in low-risk (Euroscore II &lt;4%) patients over 75 years.1
Evidence of this treatment with self-expandable supraanular bioprothesis Evolut have widely proven to be no inferior to surgical valve replacement.2 Nevertheless, experience of the annular self-expandable prothesis Portico available in this population is scarce.

Purpose
We present our early experience with the annular self-expandable prothesis Portico in our low-risk population.

Methods
We retrospectively studied 219 symptomatic low-risk patients with who underwent TAVR procedure with self-expandable valves between 2018 and 2021. Assessment included echocardiogram, immediate and 30-day follow-up, as well as last clinical visit follow-up. 92 subjects received an annular Portico prothesis. Our reference group was the suprannular prothesis Evolut (n=127), already validated for low-risk patients in clinical trials.2

Results
The mean age of the patients was 79 years, 43.4% were women, and all the patients were at low surgical risk (2.2 [1.6; 3.0]). No significant differences could be appreciated in baseline demographics and echocardiographic characteristics except for body mass index (BMI), which was higher in the Portico group (p&lt;0.001) (Table).
Procedure length was similar, with the particular need of higher predilation in the Portico group according to recommendations. Both self-expandable prothesis had similar rates of intraprocedural atrioventricular block, bleeding, vascular complications, stroke, and new onset atrial fibrillation.
Mean aortic-valve gradients before discharge were lower at the suprannular Evolut group than in the annular Portico group, and immediate residual aortic regurgitation was almost inexistent in both groups (Table 1).
At a 30-day follow up, the incidence of major adverse cardiac events was low and similar among groups (p=0.6) (Figure 1), with no significant differences in the incidence of permanent pacemaker implantation, heart failure admission, stroke, bleeding o vascular complication (Figure 1).

Conclusion
Annular aortic self-expandable prothesis Portico is a feasible alternative for patients with AS and low surgical risk who undergo TAVR procedure.

Funding Acknowledgement
Type of funding sources: None.
Impact of proportionate versus disproportionate mitral regurgitation on acute procedural changes and clinical outcomes following transcatheter mitral valve repair
Authors: Kronzer E , Pislaru S , Padang R , Oguz D , Nkomo V , Oh J , Alkhouli M , Guerrero M , Reeder G , Eleid M , Rihal C , Thaden J 
Published: October 2022

Abstract

Background
Transcatheter mitral edge-to-edge repair (TEER) with MitraClip offers a less invasive alternative for patients with severe, symptomatic mitral regurgitation (MR) who are considered high risk for surgery. However, patient selection for TEER remains challenging given the variability in underlying MR pathology and current discordance among studies regarding predictors of procedural efficacy and clinical outcomes.

Purpose
This study aimed to assess acute procedural changes and long-term outcomes in patients who underwent TEER according to the proportionality of MR, defined as the ratio of the effective regurgitant orifice area (EROA) and left ventricular end-diastolic volume (LVEDV).

Methods
We analyzed patients who underwent TEER at our institution between 2014 and 2020 with available biplane left ventricular volume measurement. Relevant clinical comorbidities, demographics, and anthropometrics, along with pertinent pre- and post-procedural echocardiogram measurements, were obtained by review of the electronic medical record. The EROA to LVEDV index was calculated for all patients who were then stratified by quartiles. Patients with an EROA/LVEDV index in the lowest quartile were defined as having the most proportionate MR and those with an index in the highest quartile were defined as the most disproportionate MR. Baseline and post-TEER parameters were used to assess acute procedural and longitudinal outcomes.

Results
Baseline clinical and echocardiographic parameters of the 230 subjects according to quartile are shown in the table. Following TEER, there was a larger reduction in the left ventricular end-diastolic diameter and increased MR reduction with increasingly disproportionate MR (p=0.03 and p=0.05, respectively). The change in ejection fraction pre- versus post-TEER did not significantly differ across groups (p=0.64). Median follow up time was 1.7 (0.7–3.5) years; mortality occurred in 77 patients (33.5%) and heart failure hospitalizations occurred in 20 patients (8.7%) during follow up. No significant difference in all-cause mortality or post-procedural heart failure hospitalizations was identified across groups.

Conclusions
In our series, patients with proportionate MR were similarly symptomatic to those with disproportionate MR but had less severe MR with increased comorbidities. Post-TEER MR grade was similar between groups. Longer-term follow up in larger groups of patients is needed to determine the clinical implications.

Funding Acknowledgement
Type of funding sources: None.
Experience of the combined use of the cusp-overlap projection and auricular pacing in transcatheter aortic-valve replacement with the self-expanding valves
Authors: Tamargo M , Gutierrez E , Vazquez M E , Sanz-Ruiz R , Diez-Delhoyo F , Soriano J , Elizaga J , Fernandez-Aviles F 
Published: October 2022

Abstract

Introduction
Need of permanent pacemaker implantation (PPI) continues to be an undesirable side-effect after transcatheter aortic-valve replacement (TAVR), mostly in self-expandable (SE) valves. Recently, different techniques have arisen, as the cusp-overlap projection (COP) to better control TAVR implantation depth, and the sequential atrial pacing (AP) after deployment to test atrioventricular (AV) conduction. However, the combination of both techniques has not been tested yet. We sought to determine if the combination of COP and AP can decrease the need of PPI after SE aortic prothesis.

Methods
We retrospectively studied 253 patients in sinus rhythm who underwent TAVR procedure with SE valves between 2018 and 2021, and compared standard implantation (n=143) with the combined use of COP and AP (n=110). Patients with permanent atrial fibrillation or previous pacemaker were excluded. Assessment included EKG, imaging, immediate and 30-day follow-up. AP was performed after TAVR in the absence of complete AV block at rates of 70 to 120 beats/min (or until AV Block was observed).

Results
Median patient age was 80 [75–85] years old and 52.2% were female. No significant differences could be appreciated in baseline demographics or treatment. Both cohorts had similar EKG intervals and similar rates of conduction disturbances (Table 1). Patients with CO+AP displayed bigger outflow tract perimeters (p=0.003). Also, the CO+AP cohort underwent more frequent predilation prior to valve deployment (p&lt;0.001).
During TAVR complete AV block occurred in 4.6% of the CO+AP cohort vs 14.8% in the standard group (p=0.002). Among patients with transient or no conduction disturbances immediately after deployment, AP showed Wenckebach phenomenon in 22 subjects at a median heart rate of 110 bpm. PPI was considered within 24 hours when Wenckebach phenomenon developed below 90 bpm. Testing atrio-his conduction led to a significant decrease in the next 24-hour surveillance with a temporary pacemaker in the COP+AP cohort (23.1% vs 90.2% in the standard cohort, p&lt;0.0001). Time of hospitalization was significantly reduce in the COP + AP cohort (mean stay 2 [1; 3] days vs 5 [4; 8] days in the standard cohort, p&lt;0.0001), and the total amount of total PPI at that time was still lower CO+AP group (12.7% in CO+AP group vs 21.0% in the standard, p=0.121) (Figure 1).
On a 30-day follow-up, the rate of PPI after TAVR remained significantly decreased in the COP+AP cohort (p=0.039, Figure 1).

Conclusion
Combining COP with AP reduces the need of immediate and short-term PPI and reducing on-admission conduction surveillance and hospitalization stay after self-expandable TAVR.

Funding Acknowledgement
Type of funding sources: None.